Mast cell activation syndrome (MCAS) affects more than 15% of the U.S. population but evades most practitioners’ radar. Just five years ago, it wasn’t even on my radar, despite already having 20 years of experience as a clinician at that time. The more I dug (similar to leaky gut and post-COVID syndrome), the more I found my patients were suffering from this disorder.
Manesh Girn, PhD
Dr. Manesh Girn is a postdoctoral neuroscientist specializing in psychedelic drugs at the University of California, San Francisco.Working closely with psychedelic research pioneer Dr. Robin Carhart-Harris, he conducts neuroimaging research on the neural mechanisms underlying the psychedelic experience and psychedelic-assisted psychotherapy in humans. He has been lead or co-author of over 20 peer-reviewed publications to date on topics including psychedelics, the default mode network, abstract cognitive processes, and brain network organization. Manesh also runs a popular digital platform on Instagram and YouTube called “The Psychedelic Scientist”; and serves as the chief research officer at EntheoTech Bioscience, a bioscience company focused on psychedelic-assisted psychotherapy and multidisciplinary mental health solutions. Find out more about Manesh and get in touch at www.maneshgirn.com.